Pharma Stability: Insights, Guidelines, and Expertise
Risk assessment models in the pharmaceutical industry are structured tools used to evaluate the potential impact of deviations, assign severity levels, and prioritize corrective and preventive actions (CAPA). These models guide decision-making by balancing three key dimensions:
Click to read the full article.
Data trending refers to the analysis of historical equipment data—such as temperature, humidity, light exposure, or vibration—collected over time to identify patterns, anomalies, and deviations. In the stability testing context, trending helps uncover:
Click to read the full article.
Any deviation from approved protocols in a GMP environment can raise concerns during audits or inspections. In stability testing, the consequences are even more significant due to the time-sensitive and data-driven nature of the studies.
Click to read the full article.
Environmental chambers, temperature loggers, light sensors, and humidity controllers are all critical equipment used in pharmaceutical stability programs. A malfunction in any of these systems—no matter how brief—can lead to:
Click to read the full article.
Internal audits serve as a critical checkpoint for ensuring that pharmaceutical companies remain compliant with global GMP standards. One area that frequently draws attention during these audits is how equipment deviations—such as temperature spikes in stability chambers or calibration lapses in UV meters—are handled, documented, and resolved.
Click to read the full article.
In pharmaceutical manufacturing and stability testing, deviations from approved procedures—especially those related to equipment—pose significant risks to product quality and regulatory compliance. The Quality Assurance (QA) department plays a vital role in reviewing, approving, and closing such equipment deviation reports, ensuring that every anomaly is properly documented, investigated, and resolved.
Click to read the full article.
In GMP-compliant pharmaceutical and biotechnology environments, equipment deviations are a routine reality. Whether it’s a temperature spike in a stability chamber, a malfunctioning UV meter, or an out-of-calibration balance, the implications can be significant—particularly when stability data or product quality is impacted. An effective deviation impact assessment ensures that such events are not just documented but evaluated thoroughly for their risk, scope, and potential recurrence.
Click to read the full article.
In pharmaceutical and clinical settings, the start of a stability study is a critical milestone—especially when linked to product shelf-life decisions and regulatory submissions. However, initiating a study without ensuring that all associated equipment (e.g., stability chambers, temperature/humidity monitors) is fully qualified can lead to major compliance issues. This article explores how integrating qualification protocols with study initiation ensures data integrity and regulatory success.
Click to read the full article.
In a WHO GMP-certified facility, a 25°C/60% RH chamber experienced a 6-hour temperature rise to 29°C due to a failed compressor. The excursion went undetected because the alarm system was disabled during scheduled maintenance — an oversight by the engineering team.
Click to read the full article.
Risk-based qualification involves prioritizing qualification efforts based on the potential impact of equipment on product quality and patient safety. It is a regulatory-recommended approach that aligns with ICH Q9 (Quality Risk Management), GAMP5, and current FDA and EMA guidance.
Click to read the full article.